2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Cell Expansion, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Neonatal, Young Adult, Animal Model
PAPER

1509 Combination of surovatamig CD19- and AZD5492 CD20-targeted T cell engagers overcomes antigen escape in preclinical models of B-cell malignancy

Taylor Foreman, Nazli Jafarzadeh2, Shramana Guchhait3, Abigail Lara4, Thomas Ciucci5, Corinne Cayatte, PhD6
1 AstraZeneca, Gaithersburg, Maryland, United States
2 AstraZeneca, Gaithersburg, Maryland, United States
3 AstraZeneca, Gaithersburg, Maryland, United States
4 AstraZeneca, Gaithersburg, Maryland, United States
5 AstraZeneca, Gaithersburg, Maryland, United States
6 AstraZeneca, Gaithersburg, Maryland, United States

Introduction

Antigen escape, whereby tumor cells downregulate or lose the target antigen under therapeutic pressure, represents a well-characterized mechanism of resistance to single-antigen-targeted T cell engagers (TCEs). To address this challenge, deepen therapeutic responses, and broaden tumor coverage, we are developing two differentiated TCEs for B-cell malignancies: surovatamig, a CD3-affinity-tuned, CD19-targeting TCE, and CD20 TITAN (AZD5492), a CD8-guided, CD20-targeting TCE. We evaluated the combination potential of these two agents using a series of in vitro and in vivo preclinical models.

Methods

In vitro assays included T cell activation, cytokine release, and cytotoxicity against B-cell tumor lines. To model antigen heterogeneity, cell lines were engineered with knockdown of either CD19 or CD20, enabling evaluation of combination activity against mixed antigen-positive and antigen-negative populations. Cytokine profiling of key inflammatory mediators was used to characterize the safety margin of the combination relative to each monotherapy and to glofitamab (2+1 CD20 TCE). In vivo studies employed humanized murine xenograft models bearing tumors with dual or single CD19/CD20 antigen expression. Primary endpoints were tumor burden reduction and serum cytokine levels.

Results

In vitro assessment of surovatamig and AZD5492 on dual CD19+/CD20+ B cell lines, in monotherapy or combination, showed potent cytolysis associated with significantly lower cytokine-release than glofitamab.

In a disseminated CD19+/CD20+ model (Toledo-Luciferase), humanized mice were treated with equimolar doses of AZD5492, surovatamig, the combination of both agents, or glofitamab. All treatment groups demonstrated significant anti-tumor activity compared to vehicle-treated controls at study end. Anti-tumor activity was comparable between monotherapy, and combination arms (surovatamig 86±8%; AZD5492 74±14%, surovatamig +AZD5492 82±10%, glofitamab 74±14%), confirming that the two agents do not exhibit pharmacological interference when both target antigens are co-expressed on tumor cells. Cytokine levels measured 3 hours post-dose were significantly lower for surovatamig and AZD5492, alone or in combination, than for glofitamab [TNF-a(pg/mL): PBS 6±2, surovatamig 169±43; AZD5492 308±100, surovatamig +AZD5492 168±51, glofitamab 1456±604), supporting a differentiated therapeutic window.

In a second disseminated model (Raji-Luciferase), we characterized the dose-efficacy relationship of the combination. Both agents showed dose-dependent anti-tumor activity. At sub-efficacious doses, surovatamig and AZD5492 monotherapies reduced tumor burden by 25±10% and 38±22%, respectively; the combination achieved 83±14% inhibition, demonstrating a clear additive benefit under suboptimal conditions.

We then assessed the ability of the combination to control heterogeneous tumor populations containing antigen-negative cells. In vitro, surovatamig plus AZD5492 fully eliminated a 50/50 mixture of CD19-negative and CD20-negative cells, whereas either monotherapy failed to clear the antigen-negative fraction. In vivo, in a subcutaneous heterogeneous tumor model (TMD8), the TCE combination achieved 89±2% tumor growth inhibition versus 51±9% for surovatamig and 68±6% for AZD5492 alone, confirming that dual-antigen targeting overcomes single-antigen escape.

Conclusion

The combination of surovatamig and AZD5492 delivers superior anti-tumor efficacy against both homogeneous and heterogeneous B-cell tumors while maintaining a favorable cytokine-release profile. These preclinical data provide a strong rationale for clinical advancement of this combination strategy.

Taylor Foreman: AstraZeneca - Current equity holder in publicly-traded company; AstraZeneca - Current Employment